Monday, October 25, 2021 7:06:30 PM
Got it!
Recent AGEN News
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 • Business Wire • 04/03/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:29 PM
- アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表 • Business Wire • 04/02/2026 04:31:00 AM
- Agenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR • Business Wire • 04/02/2026 04:27:00 AM
- Agenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird • Business Wire • 04/02/2026 03:50:00 AM
- Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer • Business Wire • 04/01/2026 11:30:00 AM
- Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access • Business Wire • 03/26/2026 08:52:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:24:51 PM
- Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer • Business Wire • 03/17/2026 08:40:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 09:19:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:15:01 PM
- Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized • Business Wire • 03/16/2026 11:30:00 AM
- Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs • Business Wire • 03/10/2026 11:30:00 AM
- Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update • Business Wire • 03/04/2026 09:30:00 PM
- Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL • Business Wire • 02/19/2026 08:15:00 PM
- Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors • Business Wire • 02/09/2026 06:00:00 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 01/23/2026 01:57:55 PM
- Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab • Business Wire • 01/21/2026 12:30:00 PM
- Agenus to Host First 2026 Stakeholder Webcast • Business Wire • 01/20/2026 11:24:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 01:25:26 PM
- アジーナス、BOT+BALを推進し、米国での製造体制を強化するため、ザイダス・ライフサイエンスとの1億4100万ドル規模の戦略的提携を締結 • Business Wire • 01/16/2026 01:05:00 AM
- Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA • Business Wire • 01/16/2026 01:05:00 AM
- Agenus annonce la conclusion d'un accord de collaboration stratégique d'une valeur de 141 millions de dollars avec Zydus Lifesciences afin de faire progresser le développement du BOT+BAL et de renforcer la capacité de production aux États-Unis • Business Wire • 01/15/2026 06:13:00 PM
- Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness • Business Wire • 01/15/2026 12:01:00 PM
